Magnesium adipate is a magnesium salt. It was reported that treatment with a preparation containing magnesium adipate and magnesium nicotinate (in tablet or ampule form for i.v. or i.m. administration) has been useful in the treatment of patients with coronary, cerebral and peripheral atherosclerosis.

SCH-23390 is a potent and selective antagonist of the dopamine-1 and dopamine-5 receptors (Ki = 0.2 and 0.3 nM respectively). It was found to prevent death from d-amphetamine overdose in rats and has also been investigated as a potential treatment for Parkinson's Disease and Bipolar Disorder. A single clinical trial was conducted in healthy humans where SCH-23390 induced akathisia (motor restlessness). Preclinical and clinical trials as therapeutic have been discontinued due to side-effects and lack of efficacy. However, it should be noted that a C11 radiolabeled version of the compound has been synthesized and used as a PET imaging probe for the study of Parkinson's Disease and Huntington's Disease.

BW 245C is a DP receptor agonist. Systemic administration of BW 245C to healthy volunteers lead to inhibition of platelet aggregation responses to ADP. BW245C was found to be effective in reducing human intraocular pressure, but its clinical usefulness as anti-glaucoma drugs is limited by the extraocular side effects.

Tropine is a naturally-occurring tropane alkaloid, which can be obtained from tropinone under the action of Tropinone reductases I. Tropine serves as an intermediate in the synthesis of different bioactive alkaloids, including atropine. In 1950th was published an article, where was described the use tropine in the treatment of angina pectoris. But in further articles were mentioned the derivative of tropine, atropine for the treatment of this disease.

Riboflavin 5'-acetate (aka riboflavin acetate) is a derivative of riboflavin which has a single acetylation on the ribityl moiety. There is a patent which describes the use of 'riboflavin acetate' in combination with pravastatin to reduce the serum cholesterol of beagles. However, it should be noted that riboflavin tetraacetate is sometimes colloquially referred to as riboflavin acetate.

Magnesium (butyrate) dibutirate is the magnesium salts of butyric acid. Magnesium butyrate in combination with calcium butyrate as a dietary supplement supports the integrity of the colonic mucosa by supplying a primary fuel for the colonic epithelium. It is recommended for anyone with symptoms of permeable gut and also is recommended for people who have taken an extended course of broad-spectrum antibiotics. Butyrate is a short chain fatty acid that is a potent detoxifier of ammonia and neurotoxins. Butyrate also encourages the formation of friendly bacteria in the gut. Butyrate (calcium/magnesium) could be effective in treating congenital chloride diarrhea.

Silver Iodate is an odorless, white, practically insoluble in water, solid crystalline salt, with the formula AgIO3. Silver iodate can be obtained by reacting silver nitrate (AgNO3) with sodium iodate or potassium iodate. Silver iodate has been utilized as an oxidant to transform a,c-biladienes into porphyrins via cyclization. Silver iodate has been applied toward the multistep synthesis of meso- and β-substituted chlorin building blocks. Silver iodate is used to detect traces of chlorides in blood.

D-alanine is an isomer of non-essential L-amino acid. D isomer is found in the cell walls of bacteria, but not in bacterial proteins. It was discovered, that being an endogenous agonist of the glycine site of the N-methyl-d-aspartate (NMDA) receptor, D-alanine can have beneficial effects on schizophrenia.

Calcium magnesium citrate is the newer and better version of old calcium supplements. It is presumably indicated for the maintenance of healthy bones and normal nerve and muscle function.

Kasugamycin, an aminoglycoside antibiotic, potently inhibits both gram-positive and gram-negative bacteria, binds to the 30S subunit of the bacterial ribosome, and suppresses protein synthesis. Kasugamycin was studied in clinical use for urinary tract infections due to Pseudomonas aeruginosa and was investigated its therapeutic effect on respiratory infections due to Pseudomonas aeruginosa. Experiments in vitro showed that kasugamycin did not have any appreciable effect against a variety of bacteria tested. The only exceptions were several species of gram-negative bacteria, against which antibiotics that are more satisfactory already exist. That is why further evaluation of kasugamycin for potential human use as an antipseudomonal was discontinued.